A multi-institutional comparison of retrospective deformable dose accumulation for online adaptive magnetic resonance-guided radiotherapy.

Deformable dose accumulation (DDA) Deformable image registration (DIR) Multi-institutional analysis Online MR-guided radiotherapy (MRgRT)

Journal

Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 16 01 2024
revised: 07 05 2024
accepted: 08 05 2024
medline: 17 6 2024
pubmed: 17 6 2024
entrez: 17 6 2024
Statut: epublish

Résumé

Application of different deformable dose accumulation (DDA) solutions makes institutional comparisons after online-adaptive magnetic resonance-guided radiotherapy (OA-MRgRT) challenging. The aim of this multi-institutional study was to analyze accuracy and agreement of DDA-implementations in OA-MRgRT. One gold standard (GS) case deformed with a biomechanical-model and five clinical cases consisting of prostate (2x), cervix, liver, and lymph node cancer, treated with OA-MRgRT, were analyzed. Six centers conducted DDA using institutional implementations. Deformable image registration (DIR) and DDA results were compared using the contour metrics Dice Similarity Coefficient (DSC), surface-DSC, Hausdorff-distance (HD95%), and accumulated dose-volume histograms (DVHs) analyzed via intraclass correlation coefficient (ICC) and clinical dosimetric criteria (CDC). For the GS, median DDA errors ranged from 0.0 to 2.8 Gy across contours and implementations. DIR of clinical cases resulted in DSC > 0.8 for up to 81.3% of contours and a variability of surface-DSC values depending on the implementation. Maximum HD95%=73.3 mm was found for duodenum in the liver case. Although DVH ICC > 0.90 was found after DDA for all but two contours, relevant absolute CDC differences were observed in clinical cases: Prostate I/II showed maximum differences in bladder V28Gy (10.2/7.6%), while for cervix, liver, and lymph node the highest differences were found for rectum D2cm Overall, high agreement was found between the different DIR and DDA implementations. Case- and algorithm-dependent differences were observed, leading to potentially clinically relevant results. Larger studies are needed to define future DDA-guidelines.

Sections du résumé

Background and Purpose UNASSIGNED
Application of different deformable dose accumulation (DDA) solutions makes institutional comparisons after online-adaptive magnetic resonance-guided radiotherapy (OA-MRgRT) challenging. The aim of this multi-institutional study was to analyze accuracy and agreement of DDA-implementations in OA-MRgRT.
Material and Methods UNASSIGNED
One gold standard (GS) case deformed with a biomechanical-model and five clinical cases consisting of prostate (2x), cervix, liver, and lymph node cancer, treated with OA-MRgRT, were analyzed. Six centers conducted DDA using institutional implementations. Deformable image registration (DIR) and DDA results were compared using the contour metrics Dice Similarity Coefficient (DSC), surface-DSC, Hausdorff-distance (HD95%), and accumulated dose-volume histograms (DVHs) analyzed via intraclass correlation coefficient (ICC) and clinical dosimetric criteria (CDC).
Results UNASSIGNED
For the GS, median DDA errors ranged from 0.0 to 2.8 Gy across contours and implementations. DIR of clinical cases resulted in DSC > 0.8 for up to 81.3% of contours and a variability of surface-DSC values depending on the implementation. Maximum HD95%=73.3 mm was found for duodenum in the liver case. Although DVH ICC > 0.90 was found after DDA for all but two contours, relevant absolute CDC differences were observed in clinical cases: Prostate I/II showed maximum differences in bladder V28Gy (10.2/7.6%), while for cervix, liver, and lymph node the highest differences were found for rectum D2cm
Conclusion UNASSIGNED
Overall, high agreement was found between the different DIR and DDA implementations. Case- and algorithm-dependent differences were observed, leading to potentially clinically relevant results. Larger studies are needed to define future DDA-guidelines.

Identifiants

pubmed: 38883145
doi: 10.1016/j.phro.2024.100588
pii: S2405-6316(24)00058-7
pmc: PMC11176923
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100588

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

MM and DT report institutional collaborations including financial and non-financial support by Elekta AB, Philips, TheraPanacea, Dr. Sennewald, Brainlab and PTW Freiburg. MM acknowledges funding through the German Research Council (DFG), grants no. MU 4603/1-1 (PAK997/1) and ZI 736/2-1. HZ is partly supported by the grant R01-EB028324 from National Institute of Biomedical Imaging andBioengineering, NIH. All other authors do not declare financial interests/personal relationships.

Auteurs

Martina Murr (M)

Section for Biomedical Physics, Department of Radiation Oncology, University of Tübingen, Germany.

Uffe Bernchou (U)

Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Laboratory of Radiation Physics, Odense University Hospital, Denmark.

Edyta Bubula-Rehm (E)

Elekta AB, Stockholm, Sweden.

Mark Ruschin (M)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Parisa Sadeghi (P)

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Peter Voet (P)

Elekta AB, Stockholm, Sweden.

Jeff D Winter (JD)

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Jinzhong Yang (J)

Department of Radiation Physics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Eyesha Younus (E)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Cornel Zachiu (C)

University Medical Centre Utrecht, Department of Radiotherapy, 3584 CX Utrecht, the Netherlands.

Yao Zhao (Y)

Department of Radiation Physics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Hualiang Zhong (H)

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Daniela Thorwarth (D)

Section for Biomedical Physics, Department of Radiation Oncology, University of Tübingen, Germany.

Classifications MeSH